NASD · Healthcare · Biotechnology · Switzerland
BeOne Medicines Ltd ADR is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
BeOne Medicines is a global oncology company discovering and developing cancer treatments. The company markets BRUKINSA, a Bruton's tyrosine kinase inhibitor approved across multiple B-cell malignancies, and TEVIMBRA, an anti-PD-1 antibody. Its pipeline includes sonrotoclax, a lymphoma inhibitor, and solid tumor programs across breast, lung and gastrointestinal cancers.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the BeOne Medicines Ltd ADR stock.
Overvalued: intrinsic value $122.71 per share, market price $370.33, margin of safety -201.8% (as of 2026-10-30).
Discounting its cash flows at 8.6% (average of 3 methods) values the shares at $122.71; the price of $370.33 is 202% above that value.
Leak Score: 56/100 on 12 of 12 signals (Weak Signal).
3 more funds hold it; the full list is part of the paid plan.
64 more in this industry show a wider margin of safety.
ONC is overvalued (as of the 2026-10-30 close). Discounting its cash flows at 8.6% (average of 3 methods) values the shares at $122.71; the price of $370.33 is 202% above that value.
$122.71 per share (as of the 2026-10-30 close), against a market price of $370.33. That is a margin of safety of -201.8%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
56 out of 100, which we rate "Weak Signal", on 12 of 12 value investing signals.